Mr. Marc-Andre Massue reports

DIAGNOS ANNOUNCES DATE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

Diagnos Inc.'s 2021 annual general and special meeting of shareholders will be held on Sept. 10, 2021, at 10 a.m. ET.

Purposes of the meeting:

1. To receive the annual report of management, the audited consolidated financial statements of the corporation for the financial year ended March 31, 2021, and the independent auditor's report thereon;
2. To elect the directors of the corporation;
3. To reappoint Raymond Chabot Grant Thornton LLP as independent auditor of the corporation for the ensuing year and to authorize the directors to fix the auditor's remuneration;
4. To approve by ordinary resolution the amendment to the corporation's existing stock option plan to increase the maximum number of common shares that may be issued pursuant thereto from nine million to 10.2 million, as approved by the board of directors on Aug. 10, 2021;
5. To transact such other business as may properly come before the meeting or any adjournment thereof.

The corporation is strongly recommending all shareholders to vote by proxy in advance of the meeting.

Attendance/participation at the meeting

Due to COVID-19 sanitary measures, registered shareholders and non-registered holders (as defined in the management information circular available on SEDAR) who do not intend to vote at the meeting are kindly asked to participate via video conference.

Only registered shareholders and duly appointed proxyholders who intend to vote at the meeting will be able to attend the meeting in person at the corporation's head office, located at 7005 Taschereau Blvd., suite 265, Brossard, Que.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of CARA (computer-assisted retina analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is: accessible securely over the Internet; compatible with all recognized image formats and brands of fundus cameras; and EMR (electronic medical record) compatible. CARA is a cost-effective tool for screening large numbers of patients in real time. CARA complies with local regulations; is United States Food and Drug Administration cleared for commercialization in the United States; is Health Canada licensed for commercialization in Canada; and is CE marking compliant in Europe.

We seek Safe Harbor.